The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Cited by
Sorted by citations
Items 101–200 of 1,007
Cancer overdiagnosis: a biological challenge and clinical dilemma
Srivastava, S., Koay, E. J., Borowsky, A. D., Marzo, A. M. D., Ghosh, S., Wagner, P. D., & Kramer, B. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0142-8 · Cited by 349
Padhani, A. R., Lecouvet, F. E., Tunariu, N., Koh, D., Keyzer, F. D., Collins, D. J., Sala, E., Schlemmer, H. P., Petralia, G., Vargas, H. A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.033 · Cited by 333
Self-citationSuppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
Watt, M. J., Clark, A. K., Selth, L. A., Haynes, V. R., Lister, N. L., Rebello, R. J., Porter, L. H., Niranjan, B., Whitby, S., Lo, J. C. Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5758 · Cited by 332
Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS
Kautto, E. A., Bonneville, R., Miya, J., Yu, L., Krook, M. A., Reeser, J. W., & Roychowdhury, S. (2016) · Oncotarget · doi:10.18632/oncotarget.13918 · Cited by 313
Chen, C.-C., Feng, W., Lim, P. X., Kass, E. M., & Jasin, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050502 · Cited by 323
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Self-citationTakeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.037 · Cited by 317
Bono, J. S. D., Giorgi, U. D., Rodrigues, D. N., Massard, C., Sergio Bracarda, A., Pous, A. F., Arija, J. Á. A., Shih, K. C., Rădăvoi, G. D., Xu, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0981 · Cited by 311
Rice, M. A., Malhotra, S. V., & Stoyanova, T. I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 325
Karzai, F. H., VanderWeele, D. J., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., Couvillon, A., Nichols, E. H., Bilušić, M., Beshiri, M. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0463-2 · Cited by 311
Nguyen, H. M., Vessella, R. L., Morrissey, C. M., Brown, L. G., Coleman, I. M., Higano, C. S., Mostaghel, E. A., Zhang, X., True, L. D., Lam, H., et al. (2017) · The Prostate · doi:10.1002/pros.23313 · Cited by 302
Self-citationBrady, L., Kriner, M., Coleman, I. M., Morrissey, C. M., Roudier, M. P., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 310
Self-citationAparicio, A. M., Shen, L., Tapia, E. L. N., Lu, J., Chen, H.-C., Zhang, J., Wu, G., Wang, X., Troncoso, P., Corn, P. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1259 · Cited by 307
Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S. P., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam7479 · Cited by 297
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y.-C., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 297
Self-citationZadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., Syamala, S., Bango, C., Photopoulos, C., Huang, Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808834116 · Cited by 304
Self-citationNyquist, M. D., Corella, A. N., Coleman, I. M., Sarkar, N. D., Kaipainen, A., Ha, G., Gulati, R., Ang, L. S., Chatterjee, P., Lucas, J. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107669 · Cited by 297
Self-citationAn aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Chen, M., Zhang, J., Sampieri, K., Clohessy, J. G., Mendez, L., González‐Billalabeitia, E., Liu, X., Lee, Y.-R., Fung, J., Katon, J. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0027-2 · Cited by 297
Beltran, H., Oromendia, C., Danila, D. C., Montgomery, B., Hoimes, C. J., Szmulewitz, R. Z., Vaishampayan, U. N., Armstrong, A. J., Stein, M. N., Pinski, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1912 · Cited by 301
Self-citationInflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 319
Epidemiology and genomics of prostate cancer in Asian men
Zhu, Y., Mo, M., Yu, W., Wu, J., Pan, J. G., Freedland, S. J., Zheng, Y., & Ye, D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00442-8 · Cited by 293
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Welti, J. C., Sharp, A., Brooks, N. A. N., Yuan, W., McNair, C. M., Chand, S. N., Pal, A., Figueiredo, I., Riisnaes, R., Gürel, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0751 · Cited by 292
Self-citationThe Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 289
Greicius, G., Kabiri, Z., Sigmundsson, K., Liang, C., Bunte, R., Singh, M. K., & Virshup, D. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713510115 · Cited by 286
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Parolia, A., Cieslik, M., Chu, S.-C., Xiao, L., Ouchi, T., Zhang, Y., Wang, X., Vats, P., Cao, X., Pitchiaya, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1347-4 · Cited by 284
Self-citationSynthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Asim, M., Tarish, F., Zecchini, H. I., Sanjiv, K., Gelali, E., Massie, C. E., Baridi, A., Warren, A. Y., Zhao, W., Ogris, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00393-y · Cited by 291
Self-citationNext-generation sequencing to guide cancer therapy
Gagan, J., & Allen, E. M. V. (2015) · Genome Medicine · doi:10.1186/s13073-015-0203-x · Cited by 293
Epstein, J. I., Amin, M. B., Fine, S. W., Ferran Algaba, B., Aron, M., Baydar, D. E., Antonio Lopez-beltran, B., Brimo, F., Cheville, J. C., Colecchia, M., et al. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0015-ra · Cited by 290
Self-citationGiri, V. N., Knudsen, K. E., Kelly, W. K., Cheng, H. H., Cooney, K. A., Cookson, M. S., Dahut, W. L., Weissman, S. M., Soule, H. R., Petrylak, D. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00046 · Cited by 283
Self-citationHamid, A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C. P., Bernard, B. D., Loda, M. F., Corcoran, N. M., Allen, E. M. V., Choudhury, A. D., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.045 · Cited by 277
Self-citationClinical applications of the CellSearch platform in cancer patients
Riethdorf, S., O′Flaherty, L., Hille, C., & Pantel, K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.011 · Cited by 278
Quigley, D. A., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R. R., Kim, W. B., Lu, E., Schwartzman, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 279
Self-citationProstate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 274
Self-citationCancer transcriptome profiling at the juncture of clinical translation
Cieslik, M. P., & Chinnaiyan, A. M. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 266
Self-citationFOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
Adams, E., Karthaus, W. R., Hoover, E., Liu, D., Gruet, A., Zhang, Z., Cho, H., DiLoreto, R., Chhangawala, S., Liu, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1318-9 · Cited by 268
Self-citationChromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Tang, F., Xu, D., Wang, S., Wong, C. K., Martinez‐Fundichely, A., Lee, C. J., Cohen, S. M., Park, J., Hill, C. E., Eng, K. W., et al. (2022) · Science · doi:10.1126/science.abe1505 · Cited by 272
Self-citationThe kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 268
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Groner, A. C., Cato, L., de Tribolet-Hardy, J., Bernasocchi, T., Janoušková, H., Melchers, D., Houtman, R., Cato, A. C. B., Tschopp, P., Gu, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.012 · Cited by 274
Self-citationTargeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 287
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Cai, M., Song, X., Li, X., Chen, M., Guo, J., Yang, D., Chen, Z., & Zhao, S. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100962 · Cited by 278
Application of magnetic nanoparticles in nucleic acid detection
Tang, C., He, Z., Liu, H., Xu, Y., Huang, H., Yang, G., Xiao, Z., Li, S., Liu, H., Deng, Y., et al. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00613-6 · Cited by 268
Cheng, H. H., Pritchard, C. C., Boyd, T. E., Nelson, P. S., & Montgomery, B. (2015) · European Urology · doi:10.1016/j.eururo.2015.11.022 · Cited by 266
Self-citationPomerantz, M. M., Spisák, S., Li, J., Cronin, A. M., Csabai, I., Ledet, E. M., Sartor, O. A., Rainville, I. R., O’Connor, E. P., Herbert, Z. T., et al. (2017) · Cancer · doi:10.1002/cncr.30808 · Cited by 263
Self-citationRecent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 262
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Łukasik, P., Załuski, M., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062935 · Cited by 262
The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression
Espiritu, S. M. G., Liu, L., Rubanova, Y., Bhandari, V., Holgersen, E. M., Szyca, L., Fox, N. S., Chua, M. L. K., Yamaguchi, T. N., Heisler, L. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.029 · Cited by 251
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
Storm, E. E., Durinck, S., Melo, F. D. S. E., Tremayne, J. R., Kljavin, N. M., Tan, C., Ye, X., Chiu, C., Pham, T., Hongo, J.-A., et al. (2015) · Nature · doi:10.1038/nature16466 · Cited by 246
Self-citationPan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Riaz, N., Blecua, P., Lim, R. S., Shen, R., Higginson, D. S., Weinhold, N., Norton, L., Weigelt, B., Powell, S. N., & Reis-Filho, J. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00921-w · Cited by 249
Reactive oxygen species and cancer: A complex interaction
Saikolappan, S., Kumar, B., Shishodia, G., Koul, S., & Koul, H. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.020 · Cited by 253
Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.009 · Cited by 248
Self-citationScher, H. I., Graf, R. P., Schreiber, N. A., Jayaram, A., Winquist, E., McLaughlin, B., Lu, D. M., Fleisher, M., Orr, S. K., Lowes, L. E., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1621 · Cited by 238
Self-citationDNA Repair in Prostate Cancer: Biology and Clinical Implications
Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P., Olmos, D., Pritchard, C. C., Rubin, M. A., & Bono, J. S. D. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.037 · Cited by 247
Self-citationTargeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 242
Katoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 251
Boyle, H. J., Alibhai, S. M. H., Decoster, L., Efstathiou, E., Fizazi, K. S., Mottet, N., Oudard, S. M., Payne, H. A., Prentice, M., Puts, M. T. E., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.031 · Cited by 246
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
Taylor, R. A., Fraser, M. E., Livingstone, J. M., Espiritu, S. M. G., Thorne, H., Huang, V., Lo, W. W., Shiah, Y.-J., Yamaguchi, T. N., Sliwinski, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms13671 · Cited by 239
Zhang, Y., Pitchiaya, S., Cieslik, M. P., Niknafs, Y. S., Tien, J. C.-Y., Hosono, Y., Iyer, M. K., Yazdani, S., Subramaniam, S., Shukla, S. K., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0120-1 · Cited by 238
Self-citationTowards precision oncology in advanced prostate cancer
Ku, S., Gleave, M. E., & Beltran, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0237-8 · Cited by 230
Self-citationHeller, G., Mccormack, R. T., Kheoh, T. S., Molina, A., Smith, M. R., Dreicer, R., Fred Saad, C., de Wit, R., Aftab, D. T., Hirmand, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2998 · Cited by 230
Self-citationBeshiri, M. L., Tice, C. M., Tran, C., Nguyen, H. M., Sowalsky, A. G., Agarwal, S., Jansson, K. H., Yang, Q., McGowen, K. M., Yin, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0409 · Cited by 233
Prostate carcinogenesis: inflammatory storms
Bono, J. S. D., Guo, C. W., Gürel, B., Marzo, A. M. D., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., & Alimonti, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0267-9 · Cited by 240
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L. M., Greene, S., Zeng, Q., Fazli, L., Rennie, P. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08152-3 · Cited by 235
Wei, L., Wang, J., Lampert, E. J., Schlanger, S. E., DePriest, A. D., Hu, Q., Gomez, E. C., Murakam, M., Glenn, S. T., Conroy, J. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.008 · Cited by 226
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer
Drake, J. M., Paull, E., Graham, N. A., Lee, J. K., Smith, B. A., Titz, B., Stoyanova, T. I., Faltermeier, C. M., Uzunangelov, V., Carlin, D. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.007 · Cited by 223
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
CAMCAP Study Group, Wedge, D. C., Gundem, G., Mitchell, T., Woodcock, D. J., Martincorena, I., Ghori, M., Zamora, J., Butler, A. P., Whitaker, H. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0086-z · Cited by 227
Self-citationThe Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers
Morris, L. G. T., Chandramohan, R., West, L., Zehir, A., Chakravarty, D., Pfister, D. G., Wong, R. J., Lee, N. Y., Sherman, E. J., Baxi, S. S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1790 · Cited by 230
Cyclin D-CDK4/6 functions in cancer
Gao, X., Leone, G. W., & Wang, H. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.02.002 · Cited by 226
Chi, K. N., Sandhu, S. K., Smith, M. R., Attard, G., Saad, M. B., Olmos, D., Castro, E., Roubaud, G., Gomes, A. J., Small, E. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.009 · Cited by 224
Self-citationTreatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
Annala, M., Struss, W. J., Warner, E. W., Beja, K., Vandekerkhove, G. R., Wong, A., Khalaf, D. J., Seppälä, I.-L., So, A., Lo, G. K., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.023 · Cited by 218
PIK3CA in cancer: The past 30 years
Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 220
Carter, H. B., Helfand, B. T., Mamawala, M. K., Wu, Y., Landis, P., Yu, H., Wiley, K. E., Na, R., Shi, Z., Petkewicz, J., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.021 · Cited by 217
Self-citationThe metabolic co-regulator PGC1α suppresses prostate cancer metastasis
Torrano, V., Valcárcel-Jiménez, L., Cortázar, A. R., Liu, X., Urosevic, J., Castillo-Martín, M., Fernández‐Ruiz, S., Morciano, G., Caro‐Maldonado, A., Guiu, M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3357 · Cited by 220
Self-citationZhang, Y., Zheng, D., Zhou, T., Song, H., Hulsurkar, M. M., Su, N., Liu, Y., Wang, Z., Shao, L., Ittmann, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06177-2 · Cited by 219
PARP inhibitor combination therapy
Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 216
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0891 · Cited by 214
Self-citationThe Tumor Immune Contexture of Prostate Cancer
Vitkin, N., Nersesian, S., Siemens, D. R., & Koti, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00603 · Cited by 218
Dalin, M. G., Desrichard, A., Katabi, N., Makarov, V., Walsh, L. A., Lee, K.-W., Wang, Q., Armenia, J., West, L., Doğan, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0637 · Cited by 212
Self-citationPungsrinont, T., Kallenbach, J., & Baniahmad, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011088 · Cited by 218
Human endogenous retrovirus-K (HML-2): a comprehensive review
Montojo, M. G., Doucet-O’Hare, T. T., Henderson, L. J., & Nath, A. (2018) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2018.1501345 · Cited by 219
Epigenetic modulations and lineage plasticity in advanced prostate cancer
Ge, R., Wang, Z., Montironi, R., Jiang, Z., Cheng, M., Santoni, M., Huang, K., Massari, F., Lü, X., Cimadamore, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.002 · Cited by 215
Lallous, N., Volik, S. V., Awrey, S. J., Leblanc, E., Tse, R., Murillo, J., Singh, K., Azad, A., Wyatt, A. W., LeBihan, S., et al. (2016) · Genome biology · doi:10.1186/s13059-015-0864-1 · Cited by 208
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 216
van Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13084-7 · Cited by 214
Antonarakis, E. S., Velho, P. I., Fu, W., Wang, H., Agarwal, N., Santos, V. S., Maughan, B. L., Пили, Р., Adra, N., Sternberg, C. N., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00399 · Cited by 215
Self-citationProstate cancer, PI3K, PTEN and prognosis
Wise, H. M., Hermida, M. A., & Leslie, N. R. (2017) · Clinical Science · doi:10.1042/cs20160026 · Cited by 212
Hussain, M., Daignault‐Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D. R., Lonigro, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7310 · Cited by 210
Self-citationSETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways
Yuan, H., Han, Y., Wang, X., Li, N., Liu, Q., Yin, Y., Wang, H., Pan, L., Li, L., Song, K., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.022 · Cited by 211
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future PromisePreprint
Sumanasuriya, S., & Bono, J. S. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 213
Tukachinsky, H., Madison, R. W., Chung, J., Gjoerup, O. V., Severson, E. A., Dennis, L. M., Fendler, B. J., Morley, S., Zhong, L., Graf, R. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4805 · Cited by 206
Self-citationBlattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204
Self-citationShah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W. M., Armenia, J., Rockowitz, S., Drier, Y., Bernstein, B., Long, H. W., et al. (2017) · eLife · doi:10.7554/elife.27861 · Cited by 207
Self-citationRodrigues, D. N., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B. K., Seed, G., Mateo, J., Riisnaes, R., Mullane, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121924 · Cited by 209
Self-citationIntegrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M. M., Ashab, H. A.-D., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0902 · Cited by 209
Wang, J., Zou, J. X., Xue, X., Cai, D., Zhang, Y., Duan, Z., Xiang, Q., Yang, J. C., Louie, M. C., Borowsky, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4070 · Cited by 204
Ren, S., Wei, G., Liu, D., Wang, L., Hou, Y., Zhu, S., Peng, L., Zhang, Q., Cheng, Y., Su, H. L., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.027 · Cited by 198
Beltran, H., Romanel, A., Conteduca, V., Casiraghi, N. A., Sigouros, M., Franceschini, G. M., Orlando, F., Fedrizzi, T., Ku, S., Dann, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131041 · Cited by 196
Self-citationAndrogen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Coutinho, I., Day, T. K., Tilley, W. D., & Selth, L. A. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0422 · Cited by 197
Emerging Variants of Castration-Resistant Prostate Cancer
Vlachostergios, P. J., Puca, L., & Beltran, H. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0593-6 · Cited by 200
Self-citationPrecision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 199
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
